Evening of 19th June 2018

Meet the management of ADOCIA.

Adocia specializes in the development of innovative formulations of proteins and peptides already approved for the treatment of diabetes and other metabolic diseases. Adocia’s innovative reformulation approach, based on the BioChaperone^® technology platform, has enabled it to develop a broad and differentiated portfolio of clinical and preclinical products. Its business model is to license its innovations to pharmaceutical companies and to conclude partnerships such as the one signed in late April with the Chinese company Tonghua Dongbao. With the ambition to develop “medicines for all, everywhere”, Adocia has recently diversified therapeutic areas addressed and offers its technology platform to partners to optimize the development of their own injectable products.

TUESDAY 19 June 2018

NORMANDY HOTEL, 7 rue de l’Echelle, 75001 Paris

6:45 p.m. OPENING

7 p.m. ADOCIA Conference

With the participation of

– Gérard SOULA, PhD MBA, President and CEO
– Olivier SOULA, PhD, MBA, Deputy Chief Executive Officer, R&D Director
– Rémi SOULA, PhD, MBA, Business Development and Legal Director
– Valérie DANAGUEZIAN, Administrative and Financial Director

Program :

– The team
– Development model
– BioChaperone® Technology
– Pipeline of products and addressed markets
– Partnerships
– Financing and news Flow

8.30 p.m. Cocktail, discussions with management and networking